Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy: a systematic review and meta-analysis of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology

No abstract is available for this paper.

• Publication year

  2024

• Venue

  International Journal of Clinical Oncology

• Publication date

  2024-10-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10147-024-02643-8PMID 39417943
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents

  2023cited by this paper
• OUP accepted manuscript

  2022cited by this paper
• One-Day Versus Three-Day Dexamethasone with NK1RA for Patients Receiving Carboplatin and Moderate Emetogenic Chemotherapy: A Network Meta-analysis

  2022cited by this paper
• Low‐Dose Olanzapine Plus Granisetron and Dexamethasone for Carboplatin‐Induced Nausea and Vomiting in Patients with Thoracic Malignancies: A Prospective Multicenter Phase II Trial

  2021cited by this paper
• Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE

  2021cited by this paper
• Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis

  2020cited by this paper
• Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy‐Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial

  2020cited by this paper
• Antiemetics: ASCO Guideline Update.

  2020cited by this paper
• Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study.

  2020cited by this paper
• Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence

  2019cited by this paper
• One‐Day Versus Three‐Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy‐Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data‐Based Meta‐Analysis

  2019cited by this paper
• Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting

  2019cited by this paper
• Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

  2019cited by this paper
• Short-course olanzapine to prevent delayed emesis following carboplatin/paclitaxel for gynecologic cancer: a randomised study

  2019cited by this paper
• A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy: Results of the Korean South West Oncology Group (KSWOG) Study

  2018cited by this paper
• A Prospective Observational Study on Effect of Short‐Term Periodic Steroid Premedication on Bone Metabolism in Gastrointestinal Cancer (ESPRESSO‐01)

  2017cited by this paper
• Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study.

  2016cited by this paper
• A Pilot Study Evaluating Steroid-Induced Diabetes after Antiemetic Dexamethasone Therapy in Chemotherapy-Treated Cancer Patients

  2016cited by this paper
• Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.

  2016cited by this paper
• Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron

  2015cited by this paper
• Palonosetron in combination with 1‐day versus 3‐day dexamethasone for prevention of nausea and vomiting following paclitaxel and carboplatin in patients with gynecologic cancers: A randomized, multicenter, phase‐II trial

  2015cited by this paper
• Palonosetron in combination with 1-day versus 3-day dexamethasone to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin

  2015cited by this paper
• Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial.

  2012cited by this paper
• A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults.

  2011influential reference
• Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.

  2010influential reference
• Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial

  2010influential reference
• Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive

  2008cited by this paper
• Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.

  2006cited by this paper
• Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy

  2005cited by this paper
• Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer

  2005cited by this paper
• An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting.

  1997cited by this paper
• Department of

  1993cited by this paper
• Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables

  1990cited by this paper
• High-dose intravenous metoclopramide versus combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a single-blind crossover comparison of antiemetic efficacy.

  1985cited by this paper

• Practical Management of Zolbetuximab Administration: The Project VYLOY Initiative

  2025cites this paper